Key result
Beta-blocker therapy at discharge was not associated with reduced 2-year all-cause mortality in ACS patients with LVEF >=40% undergoing PCI.
Why the study?
The clinical impact of beta-blockers in patients with adequate LVEF who underwent PCI for ACS was not well defined.
Does beta-blocker therapy at discharge reduce all-cause mortality in patients with acute coronary syndrome and LVEF >= 40% without heart failure who underwent percutaneous coronary intervention?
Cohort (n=5,631)
No
Does beta-blocker therapy at discharge reduce all-cause mortality in patients with acute coronary syndrome and LVEF >= 40% without heart failure who underwent percutaneous coronary intervention?
In ACS patients with preserved or mildly reduced LVEF (>=40%) undergoing PCI, discharge beta-blocker therapy did not reduce 2-year all-cause mortality overall, though a subgroup benefit was observed in unstable angina patients during the first year.
Answers are grounded in this paper and cite their sources.
Beta-blocker discharge therapy should not yet alter practice in ACS with LVEF ≥40% post-PCI; leaves open potential early benefit in unstable angina for randomized evaluation.
Aim . To evaluate the clinical impact of β -blocker in patients with adequate left ventricular ejection function (LVEF) who underwent percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). Methods . A total of 10,724 consecutive patients who underwent PCI throughout 2013 were prospectively enrolled in the study. Among these, we analyzed 5,631 ACS patients who were discharged with LVEF≥40%. Patients were then compared according to the β -blocker prescription at discharge. Results . During a 2-year follow-up, no significant association was observed of β -blocker use with all-cause mortality (with β -blockers 47/5,043 (0.9%) vs. without β -blocker use 8/588 (1.4%); hazard ratio (HR) 0.762, 95% confidence interval 0.36 to 1.64; P=0.485), cardiac death, myocardial infarction (MI), or major adverse cardiovascular and cerebrovascular events. Subgroup analysis demonstrated that the β -blocker use at discharge reduced the 2-year mortality in patients with unstable angina (UA) (HR 0.42, 95% CI 0.19 to 0.94, P=0.034). Landmark analysis at 1 year showed that patients with UA who were discharged with β -blockers had lower mortality (HR 0.17, 95% CI 0.04-0.65, P=0.010) and cardiac death (HR 0.12, 95% CI 0.01-0.99, P=0.049) than those discharged without β -blockers. However, the benefit was lost beyond 1 year. No differences in outcomes were recorded in the AMI or overall population. Conclusions . We present that β- blocker significantly lowers the rate of all-cause death up to 1 year, in UA patients who have undergone PCI and have adequate LVEF. Its role in patients with AMI also deserves further exploration.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2020) conducted a cohort in Acute coronary syndrome with LVEF >= 40% without heart failure undergoing PCI (n=5,631). Beta-blocker therapy at discharge vs. No beta-blocker prescription at discharge was evaluated on All-cause mortality at 2 years (HR 0.762, 95% CI 0.36-1.64, p=0.485). Beta-blocker therapy at discharge was not associated with reduced 2-year all-cause mortality in ACS patients with LVEF >=40% undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: